Friday, February 23, 2007
Diagram On Brazilian Wax
think global health as a "Grand Challenge"?
According to Science, in the last seven years have been spent over 35 billion dollars to combat diseases that disproportionately affect pobres.156 A huge portion of that money comes from the rich disproportionately. Since 1999, the world's richest man, Bill Gates, has donated, through the Bill and Melinda Gates Foundation-6 billion dollars, which in broad terms is equated with the WHO budget for the same period. 157 In June 2006, the super-wealthy investor Warren Buffet (according to some the second richest man in the world) announced plans to transfer about 31 billion dollars of its 44 000 million to the Gates Foundation donate eventually double the assets of caridad.158 According to The Economist, is the rapid creation of wealth (there are now 691 000 billionaires in the world when ten years ago had 432) and an unequal distribution Today wealth that explains the enthusiasm for philanthropy deep bolsillos.159
Wealthy donors often align with global campaigns, billboards and large format involving governments, corporations, associations and foundations in areas public and private [Public-Private Partnerships, or PPP]. Goals can be as ambitious as it is wide involvement: "Make Poverty History" or "Curb Malaria, for example. The PPP is seen as a way to enforce what the P in "public" has failed and what the P in "private" has no incentive. Ten years ago, PPP had no one to be devoted to the development of "orphan drugs"-drugs that have little or no potential for financial gain, and there are now over 63 drug development projects aimed at remedying the diseases prevalent in the South global.160 prospects proceeds from the sale of "orphan drugs" has not changed, but well-endowed philanthropic foundations and to a lesser extent, governments have offered to pharmaceutical companies an array so sweet that it is impossible to refuse: the foundations and governments to provide cash and technology companies provide drug development and infrastructure for clinical trials. According to Science, for large pharmaceutical benefits model "zero profit, zero loss" include "a good public image and his introduction to the markets of developing countries, as well as make contact with researchers who help anywhere." 161 According
Eldis (entity of the Institute of Development Studies, Essex), requires about 600 million dollars over the next ten years to develop a microbicide, replicable, to remain on the shelves (in good condition) a reasonable and attractive for usuarios.162 Ideally, microbicides would give women more likely to protect themselves against HIV without having to rely on the cooperation of their partners. But gender inequality is the root of the problem, unless it is in front, a new technology may not offer a simple solution. Those working for women find that money be spent better if applied programs of empowerment of women, aimed at increasing their income and ability to assume control over their own lives. There are also numerous health and safety issues surrounding the development of microbicides, especially in the global South where the living conditions of already poor, can complicate a safe and effective. Based on historical trends, there is concern that political pressures to adopt effective microbicide could undermine the necessary rigorous testing process, and that vulnerable populations of women end up being guinea pigs (for example, one of the first tests microbicide clinical [not Starpharma] held among sex workers actually increased the incidence of HIV infection in these women) .163
global health initiatives
Table 4 provides details of seven global health initiatives-all financed through partnerships of public and private spheres. Although statistics regarding the incidence of disease in the global South can only be described in very dark-the average life expectancy has fallen in 38 countries since 1999, especially by the spread of HIV, 165 two million children die each year from diseases preventable by vaccination, 166 a child dies of malaria every 30 seconds in Africa subsahariana167 and over 8 million people become sick with infectious TB each año168-it would be unfair to rule out any of these initiatives as a categorical failure, given the daunting challenges and the relatively early stage of projects . Only one of the initiatives has over ten years and five have less than five years. (The possible exception is the program to hinder the malaria known as Roll Back Malaria Programme, the British Medical Journal in 2004 described as "a failed health initiative, due to their inability to make available in the poorest communities essential tools to combat malaria, mosquito nets, insecticides, medicines based on artemisinina.169) 
Moreover, it would be irresponsible to state that some of these categorical programs are successful. None of the initiatives is above criticism, although some are more prone to problems than others. In June 2006, The New York Times shed light on certain failures related to the fight against malaria: The Global Fund has yet to deliver at least one of the 1.8 million nets promised in Uganda in 2004, the World Bank does not have staff working in spite of malaria in 2000 claimed had halved deaths from malaria in Africa, only 8 percent of the budget for malaria in 2004 by the U.S. Agency for International Development (known worldwide by its acronym in English: USAID) was used in medicines , mosquito nets and insecticides. Requires about 600 million dollars over the next ten years to develop a microbicide, replicable, to remain on the shelves (in good condition) a reasonable and attractive to users.
Table 4: Global Health Initiatives current Focus Initiative Release Year Donor funds pledged, committed or spent in dollars Grand Challenges in Global Health Initiative170
Applying science and technology to health problems in the developing world
Gates Foundation, Wellcome Trust, the Canadian Institutes of Health Research and the Foundation
for U.S. health institutes 481.6 million
2002 governments, Gates Foundation, Hewlett Foundation, United Nations Foundation , Novartis, Statoil and other 8 600 000 000
Global Alliance for Vaccines and Immunization (GAVI)
Fund and develop vaccines for children 1999
WHO, UNICEF, World Bank, NGOs, the Gates Foundation, governments, vaccine industry (Wyeth, Chiron
Several PPP (partnerships of public and private) to develop drugs, vaccines, diagnostics, microbicides, treatment. Ode Development treatments, vaccines and diagnostics Undated
Several governments, foundations, philanthropists, corporations
1 200 million
Multi-Country HIV / AIDS Program Financing improve existing efforts in the prevention and treatment by governments and community
2000 World Bank
Multi-Country HIV / AIDS Program Financing improve existing efforts in the prevention and treatment by governments and community
2000 World Bank
1 100 million
International AIDS Vaccine Initiative Research and development of AIDS vaccine
1996 World Bank / Global Forum for Health Governments Research, Becton, Dickinson and Co.,
Foundation Gates, Continental Airlines, Deutsche AIDS-Stiftung, DHL, Google, Otto Haas Charitable Trust # 2, Pfizer, Rockefeller Foundation, Until There's A Cure Foundation, and other
100 000 000 International AIDS Vaccine Initiative Research and development of AIDS vaccine
1996 World Bank / Global Forum for Health Governments Research, Becton, Dickinson and Co.,
Foundation Gates, Continental Airlines, Deutsche AIDS-Stiftung, DHL, Google, Otto Haas Charitable Trust # 2, Pfizer, Rockefeller Foundation, Until There's A Cure Foundation, and other
Roll Back Malaria Treatment and Prevention Partnership
1998 Governments, World Bank, UN agencies, academic institutes, academics, NGOs, corporations, individuals
1998 Governments, World Bank, UN agencies, academic institutes, academics, NGOs, corporations, individuals
150 million. 171
Sources: Science January 13, 2006, p. 163, ETC Group
Sources: Science January 13, 2006, p. 163, ETC Group
The bulk of its budget was used in meetings and share consultoría.172 In general, criticism of health initiatives include high-profile mismanagement (corruption rampant in some cases), duplication, inefficiency, shortness of mindedness and lack of an "architecture" capable of uniting the global esfuerzos.173 In a time of increasing enthusiasm for the potential of nanomedicine to solve the major health challenges in the world, it is important to emphasize that any innovation will make these structural problems disappear.
"The nanotechnology cancer imaging to reduce uncertainty promises that lead to a more sensitive and accurate detection in the early stages of the disease ... These efforts erased the boundaries between what we call what we call detection and therapy. "
Adrian Lee, Professor of Medicine, Baylor College of Medicine "The nanotechnology cancer imaging to reduce uncertainty promises that lead to a more sensitive and accurate detection in the early stages of the disease ... These efforts erased the boundaries between what we call what we call detection and therapy. "
One of the most publicized areas of research in Nanomedicine involves nanoproyectiles use of gold to detect and treat cancerous tumors. The bulk of its budget was used in meetings and share consultoría.172 In general, criticism of health initiatives include high-profile bad handling (corruption rampant in some cases), duplication, inefficiency, short-sightedness and lack of an "architecture" capable of uniting the global esfuerzos.173 In a time of increasing enthusiasm for the potential of nanomedicine to resolve major health challenges in the world, it is important to emphasize that no innovaciónhará that these structural problems disappear.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment